Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.
|Articles|December 23, 2021
AJMC® in the Press, December 23, 2021
Author(s)AJMC Staff
Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.
Advertisement
A piece posted by
Advertisement
Related to this article
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.
A home-based oncology model using clear bagging is transformational for practices, protecting Medicare reimbursement and provider control, while lowering costs for patients, providers and payers
Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.
Bispecific programs differ by practice size, but shared core components can guide adaptation, experts said at a webinar for the Bispecifics Network.
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
Machine Learning Has High Accuracy, Little Prospective Validation in MPNs
3
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
4
The Next Decade of Cancer Care Is Coming Home: Who Will Be in the Driver’s Seat?
5